CyPath® Lung Test Demonstrates Clinical Utility in New Case Study
BIAF sits 57% above its 52-week low of $0.693.
Summary
bioAffinity Technologies released a clinical case study demonstrating the real-world utility of its CyPath® Lung noninvasive diagnostic test in managing high-risk lung cancer patients.
Key Events · Product Development and Regulatory · BIAF
-
Clinical Case Study Released
The company issued a press release detailing a new clinical case study for its CyPath® Lung noninvasive diagnostic test.
-
Demonstrates Clinical Utility
The case study showed CyPath® Lung supported clinical decision-making for a high-risk patient with multiple pulmonary nodules, providing confidence for continued surveillance rather than immediate invasive procedures.
-
Reduces Patient Anxiety
The negative CyPath® Lung result helped reassure both the physician and patient, aligning with Lung-RADS 3 recommendations for a six-month CT surveillance schedule.
-
Reinforces Product Value
This validation highlights the test's 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in small nodules, supporting noninvasive management of indeterminate pulmonary nodules.
Analysis · BIAF · Industrial Applications And Services
bioAffinity Technologies announced a new clinical case study validating its CyPath® Lung diagnostic test. The study highlights the test's ability to support clinical decision-making for high-risk patients with pulmonary nodules, potentially reducing anxiety and unnecessary invasive procedures. This positive clinical validation reinforces the product's value proposition and builds on recent positive developments, including increased revenue for CyPath® Lung and new expert appointments.
At the time of this filing, BIAF was trading at $1.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.69 to $46.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.